Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

Richard Pebody; Nicholas Andrews; D. M. Fleming; J. McMenamin; S. Cottrell; B. Smyth; H. Durnall; C. Robertson; W. Carman; Joanna Ellis; P. Sebastian-Pillai; Maria Zambon; C. Kearns; C. Moore; D. R.H. Thomas; John Watson

doi:10.1017/S0950268812001148

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

Richard Pebody^*, Nicholas Andrews, D. M. Fleming, J. McMenamin, S. Cottrell, B. Smyth, H. Durnall, C. Robertson, W. Carman, Joanna Ellis, P. Sebastian-Pillai, Maria Zambon, C. Kearns, C. Moore, D. R.H. Thomas, John Watson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5-to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI-6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5-to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

Original language	English
Pages (from-to)	620-630
Number of pages	11
Journal	Epidemiology and Infection
Volume	141
Issue number	3
DOIs	https://doi.org/10.1017/S0950268812001148
Publication status	Published - Mar 2013

Keywords

Influenza
influenza vaccines
vaccine-preventable diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S0950268812001148

Cite this

Pebody, R., Andrews, N., Fleming, D. M., McMenamin, J., Cottrell, S., Smyth, B., Durnall, H., Robertson, C., Carman, W., Ellis, J., Sebastian-Pillai, P., Zambon, M., Kearns, C., Moore, C., Thomas, D. R. H., & Watson, J. (2013). Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiology and Infection, 141(3), 620-630. https://doi.org/10.1017/S0950268812001148

@article{42a9f5cb1826496293f989f0945d391c,

title = "Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom",

abstract = "An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5-to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI-6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5-to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.",

keywords = "Influenza, influenza vaccines, vaccine-preventable diseases",

author = "Richard Pebody and Nicholas Andrews and Fleming, {D. M.} and J. McMenamin and S. Cottrell and B. Smyth and H. Durnall and C. Robertson and W. Carman and Joanna Ellis and P. Sebastian-Pillai and Maria Zambon and C. Kearns and C. Moore and Thomas, {D. R.H.} and John Watson",

year = "2013",

month = mar,

doi = "10.1017/S0950268812001148",

language = "English",

volume = "141",

pages = "620--630",

journal = "Epidemiology and Infection",

issn = "0950-2688",

publisher = "Cambridge University Press",

number = "3",

}

Pebody, R, Andrews, N, Fleming, DM, McMenamin, J, Cottrell, S, Smyth, B, Durnall, H, Robertson, C, Carman, W, Ellis, J, Sebastian-Pillai, P, Zambon, M, Kearns, C, Moore, C, Thomas, DRH & Watson, J 2013, 'Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom', Epidemiology and Infection, vol. 141, no. 3, pp. 620-630. https://doi.org/10.1017/S0950268812001148

TY - JOUR

T1 - Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

AU - Pebody, Richard

AU - Andrews, Nicholas

AU - Fleming, D. M.

AU - McMenamin, J.

AU - Cottrell, S.

AU - Smyth, B.

AU - Durnall, H.

AU - Robertson, C.

AU - Carman, W.

AU - Ellis, Joanna

AU - Sebastian-Pillai, P.

AU - Zambon, Maria

AU - Kearns, C.

AU - Moore, C.

AU - Thomas, D. R.H.

AU - Watson, John

PY - 2013/3

Y1 - 2013/3

N2 - An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5-to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI-6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5-to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

AB - An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42-66); age-specific adjusted VE was 87% (95% CI 45-97) in <5-year-olds and 84% (95% CI 27-97) in 5-to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI-6 to 51) overall and 72% (95% CI 15-91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42-68) and in 5-to 14-year-olds 75% (95% CI 32-91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

KW - Influenza

KW - influenza vaccines

KW - vaccine-preventable diseases

UR - http://www.scopus.com/inward/record.url?scp=84876951407&partnerID=8YFLogxK

U2 - 10.1017/S0950268812001148

DO - 10.1017/S0950268812001148

M3 - Article

C2 - 22691710

AN - SCOPUS:84876951407

SN - 0950-2688

VL - 141

SP - 620

EP - 630

JO - Epidemiology and Infection

JF - Epidemiology and Infection

IS - 3

ER -

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this